Bolt Biotherapeutics Q2 EPS $(0.48) Up From $(0.61) YoY, Sales $1.43M Up From $1.39M YoY
Portfolio Pulse from Benzinga Newsdesk
Bolt Biotherapeutics reported Q2 earnings with losses of $(0.48) per share, a 21.31% improvement from $(0.61) per share YoY. The company also reported a 2.87% increase in sales to $1.43 million from $1.39 million YoY.
August 07, 2023 | 8:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bolt Biotherapeutics reported improved Q2 earnings with reduced losses and increased sales YoY.
Bolt Biotherapeutics reported a decrease in losses and an increase in sales for Q2 YoY. This indicates a positive financial performance which could potentially lead to a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100